CompanyAIMNYSEOcala, FL

AIM ImmunoTech Inc.

AIM ImmunoTech develops dsRNA and interferon therapeutics for cancers, viral diseases, and immune disorders.

SEC EDGAR ClinicalTrials.gov aimimmuno.com

DEF 14ASep 30Latest SEC filing

Sep 14Latest story

September 2026

AIM ImmunoTech converts third Streeterville note tranche, adding $400,000 in stock swaps

Sep 14PartnershipAIM ImmunoTech Inc.

August 2026

AIM ImmunoTech CEO ties Ampligen antiviral research to military biodefense in Breaking Defense op-ed

Aug 11PeopleAIM ImmunoTech Inc.

AIM ImmunoTech reports Q2 2026 results, cites pancreatic cancer trial progress toward Phase 3

Aug 10Quarterly updateAIM ImmunoTech Inc.

AIM ImmunoTech signs manufacturing deal, ends ATM stock sale program

Aug 6PartnershipAIM ImmunoTech Inc.